Funded Health Care Startups in Dublin
Disclosed round sizes in this Dublin health care list are highly concentrated at the top: ProVerum Medical’s $80M Series B (2025-08-25) is the only disclos…
Disclosed round sizes in this Dublin health care list are highly concentrated at the top: ProVerum Medical’s $80M Series B (2025-08-25) is the only disclosed amount above $50M, while the next-largest disclosed rounds cluster much lower (e.g., Amryt Pharma $125M is shown as Post-IPO Debt in 2022-02-22, and DeepVerge $33M on 2022-03-19; among the 2025–2026 entries, amounts are mostly $15M or less, with Vertigenius at $3M on 2026-04-08). The lower end is also clear: the smallest disclosed amount is $500K for MEG Support Tools (2020-09-23).
Most recent rounds
21 shownRelated listings
Frequently asked
Which rounds are the biggest disclosed outliers in this Dublin health care set, and how far above the rest do they sit?
Two disclosed outliers stand out by amount: Amryt Pharma’s $125M Post-IPO Debt on 2022-02-22 and ProVerum Medical’s $80M Series B on 2025-08-25. Aside from those, the remaining disclosed amounts are generally well below $50M, including DeepVerge at $33M (2022-03-19) and several smaller $15M and $6M rounds.
Are there tight timing clusters in the most recent entries, or are rounds spread out across years?
Yes. In 2025–2026 alone, there are 7 of the 21 rows, with three clustered in early 2025 (Novus Diagnostics $5M on 2025-01-15; SISU Aesthetic Clinic $15M on 2025-01-08; LaNua Medical $6M on 2024-12-12 is adjacent). The full window for the 21 rows spans 2020-09-23 (MEG Support Tools) through 2026-04-08 (Vertigenius), indicating both recent activity and a multi-year runway.
Does Dublin’s geography vary within the listing, or is it centered on a single Dublin label?
Geography is overwhelmingly Dublin-focused without city sub-variation: 20 of 21 rows list “Dublin, Ireland,” and one entry specifies “Dublin, Dublin, Ireland” (Vertigenius on 2026-04-08). That concentration suggests the listing is effectively a single-city cluster rather than a multi-city one.
What stage mix dominates among the disclosed rounds, and where do unknown/undisclosed amounts appear?
Stage labeling is frequently missing: 5 of 21 rows are “Series Unknown” (e.g., Vertigenius $3M on 2026-04-08; CrannMed $15M on 2026-02-26; CroíValve $3M on 2025-07-01; MedoSync $1M on 2023-07-10; Vasorum is also “Venture - Series Unknown” on 2021-02-25). Separately, 3 of 21 rows are “undisclosed” amounts (Ostoform on 2022-10-21; Latch Medical on 2022-08-11; both with undisclosed amounts, plus they’re not used for largest/smallest comparisons).
Which stage/amount combinations are most worth prioritizing for follow-up, based on how they cluster?
Look at the repeated mid-to-large funding bands in named stages: Series B and other defined rounds reach $18M (Spectrum Life on 2024-05-27, Series B), $33M (DeepVerge on 2022-03-19, Post-IPO Debt), and $80M (ProVerum Medical on 2025-08-25, Series B). Meanwhile, multiple Seed rounds cluster around single-digit millions (Novus Diagnostics $5M on 2025-01-15; LaNua Medical $6M on 2024-12-12; SepTec $5M on 2022-11-21; Fettle $540K on 2023-08-17), making Seed opportunities a separate, lower-band cohort relative to the outlier debt/Series B events.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.